Arctic Therapeutics’ Post

🔬 💊 🦄 The European Innovation Council (#EUeic) Accelerator has a prominent health sector portfolio with more than 250 Biotech and Healthtech deeptech companies. I am proud to be in charge of about 10% of that (all with potential investment component). As part of my role, last week I had a pleasure to visit Arctic Therapeutics offices in Reykjavik and laboratories in Akureyri for their EIC Accelerator project #DNACA progress meeting. 🇪🇺🤝🇮🇸 It was great to meet again the CEO Ivar Hakonarson, Chief Strategy Officer Gulli Arnason, Laboratory Director Olga Ýr Björgvinsdóttir and their highly motivated scientific team. Arctic Therapeutics apply bioinformatic approaches and AI in drug development, as well as reducing the cost and time to bring effective treatments to the patients. Their project #DNACA, in particular is focusing on developing precision medicine drug for #Dementia #Alzheimer. https://lnkd.in/ef3AhaaE According to the World Health Organization: ☑ more than 55 million people worldwide suffer from dementia and 10 million new cases appear every year. ☑ Alzheimer disease is the most common one (60-70% of the cases). ☑ It is also the 7th leading cause of death and one of the major causes of disability and dependency among senior people. ☑ the cost for society is huge - in 2019, dementia cost economies globally 1.3 trillion US dollars. Current solutions only delay dementia progress without real disease-modifying effect. 💡 Therefore, Arctic Therapeutics led by Co-founder and Chief Medical Adviser Hakon Hakonarson has developed AT-001, a new drug with the potential to not only delay the disease onset, but to stop and revert it. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify patients with validated biomarkers. 💡 AT-001 is different in that it prevents aggregation of amyloid/tau proteins, common in many types of dementia. Their Phase IIa clinical trials have shown strong effects in the treatment of Hereditary cystatin C amyloid angiopathy (HCCAA) and it was great to learn that recently #EMA approved their protocols for the further trials and that the first patients have been already enrolled. 💡 The #EUeic has awarded € 2.5M grant and € 10M equity to support development of Arctic Therapeutics drug AT-001. The EIC Fund TS was issued, and we are looking forward to their further developments and potential successful investment round led by the qualified lead investors. Thank you for your warm welcome, meaningful discussions and all the best for the further developments! 🚀 European Innovation Council and SMEs Executive Agency (EISMEA) Philipp Spenger Jose A Morales Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development | DNACA Project | Fact Sheet | HORIZON | CORDIS | European Commissioncordis.europa.eu

Our panel entitled “Roundtable: Next-Gen Health: Navigating the Al Revolution” kicked off with a deep dive into the frontiers of emerging healthcare technology! Taking a glimpse into the future at the AI House Davos, M42 Group Chief Operating Officer Ashish Ipe Koshy and a coalition of pioneering speakers explored the ethical, medical, and legislative impacts of a tech-integrated world. As part of this defining conference, Ashish discussed how AI weaves itself into our daily lives, from improving patient experiences to shifting the healthcare investment landscape. In an era of unprecedented growth, the event provided foresight into the nuances of a technologically empowered tomorrow! #M42 #Med42 #WorldEconomicForum #AIHouseDavos #Davos Ronald M. Razmi, MD Ivar Hakonarson, Arctic Therapeutics Wei Li, BlackRock Philippe GERWILL, AI 2030 Tine Petric, Microsoft